The research group aims to overcome resistance mechanisms against the PD-1/PD-L1 blockade therapy in cancer patients by elucidating the negative immune regulatory network using CRISPR/Cas9 precise genome editing (PGE) technology. The group has a special interest on rare cancer types where immunotherapy is less explored, e.g. childhood solid cancers. Prior to the appointment, Yumeng spent a few years at the Oncology R&D headquarter at AstraZeneca in Cambridge, United Kingdom, where he identified and led early drug discovery projects for novel cancer immunotherapy targets. He started his research career in cancer immunology in 2009 with Dr. Karl-Erik Hellström at the University of Washington (USA) and trained as a PhD candidate at the Karolinska Institute (Sweden) under the supervision of Prof. Rolf Kiessling. Yumeng was born and raised in Xi’an, China, where he obtained his undergraduate degree in Life Sciences.
Yumeng Mao, PhD, group leader
Irineos Papakyriacou, Master’s thesis student
Recruitment for post-doctoral fellows, research scientists, PhD candidates and project students are ongoing. Please direct your inquiries to firstname.lastname@example.org.